Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

38.02 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,412
Open 38.02
Bid (Size) 38.17 (2)
Ask (Size) 38.21 (1)
Prev. Close 38.02
Today's Range 38.02 - 38.02
52wk Range 36.17 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.10%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
Why Pfizer Stock Is Perking Up Today
Bargain hunters appear to be circling back to the beaten-down pharma stock today. 
Via The Motley Fool

Performance

YTD
-25.83%
-25.83%
1 Month
-3.03%
-3.03%
3 Month
-5.38%
-5.38%
6 Month
-24.16%
-24.16%
1 Year
-28.32%
-28.32%

More News

Read More
This Cannabis-Based Drug Has Outperformed Pfizer's Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?
Via Benzinga
Most Active Equity Options For Midday - Wednesday, May 31
Via Talk Markets
2 Ultra-Safe Dividend Stocks to Load Up On Right Now
Via The Motley Fool
Pfizer Unusual Options Activity For May 30
Via Benzinga
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
One man’s journey with advanced prostate cancer
Via Brandpoint
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
Via The Motley Fool
2 Newly Minted AI Stocks to Buy Right Now
Via The Motley Fool
3 Stocks Worth Buying at 52-Week Lows
Via MarketBeat
How Pfizer's First-Ever Approach In Hemophilia Treatment Paid Off
Via Investor's Business Daily
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
From Pfizer Inc.
Via Business Wire
Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
Via The Motley Fool
5 Value Stocks In The Healthcare Sector
Via Benzinga
The 3 Best Healthcare Stocks to Buy for June 2023
Via InvestorPlace
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income
Via The Motley Fool
MarketBeat Week in Review – 5/22 - 5/26
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
Via Investor's Business Daily
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Via SBWire
Exposures Climate
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.